Trial Profile
A phase I study will be conducted to evaluate the safety and antiviral activity of favipiravir against Ebola virus disease.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors MediVector
- 19 Aug 2015 New trial record